+1.224.938.9523

HUMAN AMYLOID IMAGING CONFERENCE

January 16-18, 2019

Miami, Florida

HAI 2019

The 13th Human Amyloid Imaging took place in Miami, Florida on January 16-18, 2019. My co-organizers for the meeting were, once more, Bill Klunk (University of Pittsburgh), Chet Mathis (University of Pittsburgh) and Bill Jagust (University of California, Berkeley).

At HAI 2019 we had continued to emphasize ample lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Our discussions primarily sprang from brief presentations by active investigators who had reported unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.

 

To assemble HAI, we accepted and peer-reviewed only the most recent, important work, abstract submissions. The 2019 meeting drew more than 400 attendees and showcased 155 posters from research groups spanning North America, Europe, East Asia, and Australia.

In addition to these, we were pleased to welcome three keynote presentations from Drs. Richard Carson (Yale University), Michel Goedert (MRC Laboratory of Molecular Biology) and John Trojanowski (University of Pennsylvania).  The recordings of these lectures are available below.

With our many thanks to all attendees, presenters, supporters and reviewers, we look forward to another great edition of the HAI in 2020.  Until then, we invite you to review the information on our website and mobile app

Keith A. Johnson, MD
Massachusetts General Hospital/Harvard Medical School

 

HAI 2019 KEYNOTE LECTURES

HAI Conveners

Keith Johnson, MD, Massachusetts General Hospital

William Jagust, MD, University of California, Berkeley

William Klunk, MD, University of Pittsburgh

Chester Mathis, PhD, University of Pittsburgh

HAI 2019 THEME CO-CHAIRS

Tobey Betthauser, PhD, University of Wisconsin
Brad Christian, PhD, University of Wisconsin
Ansel Hillmer, PhD, Yale University School of Medicine
Milos Ikonomovic, MD, University of Pittsburgh
Laetitia Lemoine, PhD, Karolinska Institute
Beth Mormino, PhD, Stanford University
Melissa Murray, PhD, Mayo Clinic
Julie Price, PhD, Harvard Medical School
Gil Rabinovici, MD, University of California, San Francisco

HAI 2019 PROGRAM COMMITTEE

Olivier Barrett, PhD
Tammie Benzinger, MD, PhD, Washington University in St. Louis
Tobey Betthauser, PhD, University of Wisconsin
Brad Christian, PhD, University of Wisconsin
Teresa Gomez-Isla, MD, Massachusetts General Hospital
Roger Gunn, PhD, Imperial College
Kenji Ishii, MD, Tokyo Metropolitan Inst. of Gerontology
Milos Ikonomovic, MD, University of Pittsburgh
Clifford R. Jack, MD, Mayo Clinic
Robert A. Koeppe, PhD, University of Michigan
Laetitia Lemoine, PhD, Karolinska Institute
Mark Lubberink, PhD, Uppsala University
Beth Mormino, PhD, Stanford University
Melissa Murray, PhD, Mayo Clinic
Agneta Nordberg, MD, PhD, Karolinska Institute
Rik Ossenkoppele, PhD, VU University Medical Center Amsterdam
Denise Park, PhD, University of Texas
Julie Price, PhD, Harvard Medical School
Gil Rabinovici, MD, University of California, San Francisco
Susan Resnick, PhD, National Institute on Aging
Juha Rinne, MD, PhD, University of Turku
Stephen Salloway, MD, Brown University
Sandra Sanabria, PhD, Genentech
Reisa Sperling, MD, Brigham and Women’s Hospital
Rik Vandenberghe, MD, PhD, KU Leuven 
Victor Villemagne, MD, The University of Melbourne
Sylvia Villeneuve, PhD, McGill University

2019 EVENT REVIEW

PODIUM PRESENTATIONS

48 podium presentations were selected from 210 submitted abstracts featured over 2.5 days.

KEYNOTE LECTURES

Richard Carson, Michel Goedert, John TrojanowskiReview all keynote videos here.

POSTER SESSIONS

210 abstract submissions with 155 poster presentations in five sessions.

PANEL DISCUSSIONS

9 podium presentation sessions were each followed by 30 minute panel discussions and Q&A sessions.

OBJECTIVES

1.

Attendees will have the opportunity to review the basic, fundamental principles of amyloid and tau PET imaging, including radiochemistry and radio-tracer synthesis, PET acquisition and data processing, including application of corrections for the partial volume effect and co-registration with structural data.  Particular attention will be given to the assessment of longitudinal PET data as it relates to methods of analysis and comparison to other domains of data, including structural and functional brain imaging data, and clinical and cognitive outcomes.

2.

Data analysis procedures discussed will include voxel-based and region-based approaches, masking for vulnerable regions, and choice of statistical procedures and specific use of control groups from older age groups.

3.

The concept of dichotomous versus continuous measures will continue to be extensively discussed, and the attendees should be able to characterize the advantages and disadvantages of both dichotomized and continuous variable approaches to analyses with respect to specific purposes or intended uses of the outcome.

4.

Attendees will have the opportunity to evaluate and compare amyloid and tau PET data in specific clinical and clinical research contexts, including review of typical findings in Alzheimer’s disease dementia, mild cognitive impairment due to Alzheimer’s disease, and in clinically normal individuals. These phenomena will also be related to familial forms of the disease and to non-AD processes such as fronto-temporal lobar degeneration and dementia with Lewy Bodies, and chronic traumatic encephalopathy.

COUNTDOWN TO 2019 CONFERENCE

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

COUNTDOWN TO ABSTRACT/REGISTRATION CLOSING

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)